Picture loading failed.

Anti-SARS-CoV-2 Spike therapeutic antibody (Pre-made Bamlanivimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Bamlanivimab (INN, codenamed LY-CoV555) is a monoclonal antibody developed by AbCellera Biologics and Eli Lilly as a treatment for COVID-19. The drug was granted an emergency use authorization (EUA) by the US Food and Drug Administration (FDA) in November 2020, and 950,000 doses have been bought by the US government as of December 2020. In April 2021, the EUA was revoked.

Order informatioin

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-045-1mg 1mg 3090
GMP-Bios-ab-045-10mg 10mg 21890
GMP-Bios-ab-045-100mg 100mg 148000
GMP-Bios-ab-045-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-SARS-CoV-2 Spike therapeutic antibody (Pre-made Bamlanivimab biosimilar,Whole mAb)
INN Name Bamlanivimab
TargetSARS-CoV-2 Spike
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI Structure7l3n:DE/7kmg:AB:DE
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2020
Year Recommendedna
CompaniesAbcellera;Eli Lilly and Company;National Institute of Allergy and Infectious Diseases
Conditions ApprovedCOVID-19
Conditions Activena
Conditions Discontinuedna
Development TechBaiting from convalescent human B-cells